Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates

M. P. De Carolis, I. Bersani, G. De Rosa, F. Cota, C. Romagnoli

Research output: Contribution to journalArticle

Abstract

This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.

Original languageEnglish
Pages (from-to)47-49
Number of pages3
JournalIndian Pediatrics
Volume49
Issue number1
DOIs
Publication statusPublished - Jan 2012

Keywords

  • Ibuprofen
  • Patent ductus arteriosus
  • Preterm
  • Prophylaxis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates'. Together they form a unique fingerprint.

  • Cite this